Pharmabiz1h
Celltrion’s Avtozma, a biosimilar to Actemra receives US FDA approval to treat RA, GCA, pJIA, sJIA and Covid-19
Jersey City, New Jersey Saturday, February 1, 2025, 16:00 Hrs [IST] ...
Monthly Prescribing Reference17h
FDA Approves Tocilizumab Biosimilar Avtozma
The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.
Healio15h
FDA approves third Actemra biosimilar; second available in intravenous, subcutaneous forms
The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both ...
Contract Pharma22h
FDA Approves Celltrion’s Biosimilar to ACTEMRA
The U.S. Food and Drug Administration (FDA) has approved Celltrion’s AVTOZMA (CT-P47, tocilizumab-anoh) in both an ...
The American Journal of Managed Care17h
FDA Approves Celltrion’s Tocilizumab-anoh, Biosimilar to Actemra
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.
centerforbiosimilars21h
FDA Approves Celltrion's Avtozma as Third Tocilizumab Biosimilar
The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.